Evidence map›Paper›PMID 39122503›Full record

ReviewDermatology practical & conceptual2024

Interleukin-13 Inhibitors in the Treatment of Atopic Dermatitis: The Role of Tralokinumab.

Annunziata Dattola, Martina Tolone, Emanuele Amore, Luigi Bennardo, Federica Trovato, Simone Amato, Teresa Grieco, Antonio Giovanni Richetta, Giovanni Pellacani, Nevena Skroza and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Dermatology practical & conceptual, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. IFN Lambda Deficiency Contributes to Severe COVID-19 Outcomes.International journal of molecular sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Annunziata DattolaDepartment of Dermatology University of Rome "La Sapienza", Rome, Italy.
Martina ToloneDepartment of Health Sciences- Unit of Dermatology, Magna Graecia University, Catanzaro, Italy.
Emanuele AmoreDepartment of Dermatology University of Rome "La Sapienza", Rome, Italy.
Luigi BennardoDepartment of Health Sciences- Unit of Dermatology, Magna Graecia University, Catanzaro, Italy.
Federica TrovatoDepartment of Dermatology University of Rome "La Sapienza", Rome, Italy.
Simone AmatoDepartment of Dermatology University of Rome "La Sapienza", Rome, Italy.
Teresa GriecoDepartment of Dermatology University of Rome "La Sapienza", Rome, Italy.
Antonio Giovanni RichettaDepartment of Dermatology University of Rome "La Sapienza", Rome, Italy.
Giovanni PellacaniDepartment of Dermatology University of Rome "La Sapienza", Rome, Italy.
Nevena SkrozaDermatology Unit 'Daniele Innocenzi', Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome Polo Pontino, Latina, Italy.
Steven Paul NisticòDepartment of Dermatology University of Rome "La Sapienza", Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe advent of biotechnological drugs has significantly changed the management of atopic dermatitis (AD) and the approach to the moderate-to-severe form of this chronic relapsing disease.

objectivesThe aim of our review is to summarize the current literature on anti-interleukin (IL)-13 in atopic dermatitis.

methodsA literature search was organized and a systematic review was performed to summarize the most recent evidence supporting the efficacy and safety of tralokinumab.

resultsTralokinumab (anti-IL-13) 300 mg every 2 weeks subcutaneously has proven effective in several clinical trials in adults and adolescents with moderate to severe atopic dermatitis inadequately controlled with other topical or systemic therapies. Tralokinumab was found to be significantly superior in terms of efficacy in reducing Investigator's Global Assessment (IGA), Eczema Area and Severity Index (EASI) -75, Numeric Pain Rating Scale (NRS) pruritus, and Dermatology Life Quality Index (DLQI) scale numbers. During follow-up, tralokinumab was well tolerated with limited severity of adverse events.

conclusionsTralokinumab leads to statistically significant improvements in disease severity and outcome scores. It represents an effective treatment option for adults with moderate to severe AD, but further large-scale studies are needed to verify long-term superiority over other treatments.

Identifiers

PMID39122503
PMCPMC11314215

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.